Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-219328
Filing Date
2026-05-12
Accepted
2026-05-12 16:00:41
Documents
83
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q klrs-20260331.htm   iXBRL 10-Q 2755126
2 EX-31.1 klrs-ex31_1.htm EX-31.1 18076
3 EX-31.2 klrs-ex31_2.htm EX-31.2 18021
4 EX-32.1 klrs-ex32_1.htm EX-32.1 9761
5 EX-32.2 klrs-ex32_2.htm EX-32.2 9759
  Complete submission text file 0001193125-26-219328.txt   10770841

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT klrs-20260331.xsd EX-101.SCH 1546483
87 EXTRACTED XBRL INSTANCE DOCUMENT klrs-20260331_htm.xml XML 1747019
Mailing Address 400 CONNELL DRIVE SUITE 5500 BERKELEY HEIGHTS NJ 07922
Business Address 400 CONNELL DRIVE SUITE 5500 BERKELEY HEIGHTS NJ 07922 650-249-2727
Kalaris Therapeutics, Inc. (Filer) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39409 | Film No.: 26968262
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)